University of Hertfordshire

From the same journal

Bio-pharma: a financialized business model

Research output: Contribution to journalArticlepeer-review


  • 904176

    Accepted author manuscript, 192 KB, PDF document

  • T. Andersson
  • P. Gleadle
  • C. Haslam
  • N. Tsitsianis
View graph of relations
Original languageEnglish
Pages (from-to)631-641
Number of pages11
JournalCritical Perspectives on Accounting
Publication statusPublished - 2010


In this paper, we construct a complementary financialized business model of SME bio-pharma that reveals how the product innovation and development process conjoins with speculative forces in capital markets. To conceptualise this descriptive business model we employ three organising elements: narratives about pipeline progress that may (or may not) lead to additional funding from equity investors or other investing partners, capital market conditions that impact on the supply of funding and market valuations and the variable motivations of equity investors who are not in a development marathon but a relay race anxious to pass on ownership and extract higher returns on invested capital through realised market value. Bio-pharmas are, in effect, constituted as investment portfolios of innovations where products in pipeline and firms trade for shareholder value. In this speculative innovation, capital market liquidity business model complementary narratives and favourable capital market conditions are required to keep it all going.


Original article can be found at: Copyright Elsevier Ltd.

ID: 82257